• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Aymen Elfiky, MD, MPH


  • Elfiky AA, Jiang Z.The PI3 Kinase Signaling Pathway in Prostate Cancer.Curr Cancer Drug Targets. 2013 Feb 1;13(2):157-64.
  • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.J Clin Oncol. 2012 Nov 19.
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.BJU Int. 2012 Aug 29.
  • Elfiky AA, Sonpavde G.Novel molecular targets for the therapy of renal cell carcinoma.Discov Med. 2012 Jun;13(73):461-71.
  • Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.Urol Oncol. 2010 May 5.